1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Issue 10088 (24th June 2017) Authors: El-Khoueiry, Anthony B; Sangro, Bruno; Yau, Thomas; Crocenzi, Todd S; Kudo, Masatoshi; Hsu, Chiun; Kim, Tae-You; Choo, Su-Pin; Trojan, Jörg; Welling, Theodore H; Meyer, Tim; Kang, Yoon-Koo; Yeo, Winnie; Chopra, Akhil; Anderson, Jeffrey; dela Cruz, Christine; Lang, Lixin; Neely, Jaclyn; Tang, Hao;... Journal: Lancet Issue: Volume 389:Issue 10088(2017) Page Start: 2492 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗